Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Learn about the benefits that become permanent features of Medicare in 2026 and how they have been changed or updated since ...

Some patients who face access restrictions may end up not using any medication, the analysts at GoodRx warn. U.S. commercial ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

President Trump issued an Executive Order (the EO) titled, “Lowering Drug Prices By Once Again Putting Americans First,” ...

Health insurance is covering fewer medications, with Medicare patients facing stricter restrictions. Profit-driven ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

Many Medicare recipients are benefiting from changes that make prescriptions more affordable. But you can still make other ...